Abstract:Ovarian cancer is a clinical type of gynecological malignant tumor with poor prognosis and a high mortality rate. At present, the primary treatment method used is surgery, with chemotherapy as an ajdunctive therapy. Thus, new short-term treatments should be identified. The aim of the present study was to investigate the short-term curative effects and safety of docetaxel combined with intraperitoneal cisplatin chemotherapy and hyperthermia treatment of advanced ovarian cancer. A total of 112 cases of advanced (stage III-IV) ovarian cancer patients confirmed by clinical diagnosis between October 2014 and December 2015 were included in the study. The patients were randomly divided into the study and control groups (n=56 cases). The control group was treated with docetaxel and intraperitoneal cisplatin hyperthermic perfusion chemotherapy, while the study group was treated with docetaxel venous chemotherapy and intraperitoneal cisplatin cyclical hyperthermic perfusion chemotherapy with BR-TRG-1 body cavity hyperthermic perfusion treatment system. Clinical treatment results for short-term curative effects and adverse reactions were compared and analyzed 8 weeks after treatment. The total effective rate of the study and control groups were 87.5 and 62.5%, respectively, and the difference was statistically significant (P<0.05). The controlled rate of ascites, remission rate of tumor and descent rate of CA125 of patients in the study group were better than patients in the control group (P<0.05). The rate of adverse reactions of patients in the study group was 39.3%, and the grade of toxicity was from I to II, while the rate of adverse reactions of patients in the control group was 55.4%, and the grade of toxicity was from II to III. The difference between the two groups was statistically significant (P<0.05). In conclusion, applying the combination of docetaxel, intraperitoneal cisplatin hyperthermic perfusion chemotherapy and hyperthermia to treat advanced ovarian cancer can improve the curative effects with little toxicity; thus, it is worthy of promotion and application.

The Progress of Antitumor Interstitial Treatment Strategy of Malignant Ovarian Cancer *

Advances in ovarian tumor stem cells and therapy

Current Status and Challenges of Treatment on Colorectal Cancer Peritoneal Metastasis with Ovarian Metastasis

The Impact of Neoadjuvant Chemotherapy on the Tumor Microenvironment in Advanced High-Grade Serous Carcinoma

Ovarian cancer: Diagnosis and treatment strategies (Review)

Nanotechnology-integrated ovarian cancer metastasis therapy: Insights from the metastatic mechanisms into administration routes and therapy strategies

Mechanisms and Advances in Anti-Ovarian Cancer with Natural Plants Component

Mitochondrial integration and ovarian cancer chemotherapy resistance

How to win the ovarian cancer stem cell battle: destroying the roots

Eliminating Ovarian Cancer Stem Cells: A Potential Therapeutic Target for Ovarian Cancer Chemoresistance

New Developments in Molecular Targeted Therapy of Ovarian Cancer.

Immunotherapy for Ovarian Cancer: Adjuvant, Combination, and Neoadjuvant

Targeting tumor microenvironment in ovarian cancer: Premise and promise.

Immunotherapy for Ovarian Cancer: Disappointing or Promising?

Docetaxel Combined with Intraperitoneal Hyperthermic Perfusion Chemotherapy and Hyperthermia in the Treatment of Advanced Ovarian Cancer.

Targeted therapy and immunotherapy: Diamonds in the rough in the treatment of epithelial ovarian cancer

Tumor Microenvironment in Ovarian Cancer: Function and Therapeutic Strategy

Intraperitoneal chemotherapy in recurrent ovarian cancer

Research progress in intratumoral heterogeneity and clinical significance of ovarian cancer

Nanoparticles in precision medicine for ovarian cancer: From chemotherapy to immunotherapy

Protection of Ovarian Function During Chemotherapy for Ovarian Cancer.